AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9342783 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (MLT; 3 mg or 9 mg)
Number of subjects: 6
Study 9342783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8261880 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 90
Study 8261880 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 90
Study 8261880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90
Study 8261880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 4041370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A alone
Number of subjects: 12
Study 4041370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A in combination with antilymphocyte serum
Number of subjects: 12
Study 29561377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-mm-wide titanium implant
Number of subjects: 57
Study 29561377 — intervention group
Group type: COMPARATOR
Intervention: 3.75-mm-wide titanium implant
Number of subjects: 57
Study 29561377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 57
Study 26911970 — intervention group
Group type: EXPERIMENTAL
Intervention: Human placental extract (HPE)
Number of subjects: 78
Study 26911970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 78
Study 24661578 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery using a high‐speed handpiece and a piezotome
Number of subjects: 20
Study 24661578 — intervention group
Group type: COMPARATOR
Intervention: Regular surgery using a high‐speed handpiece and an elevator
Number of subjects: 20
Study 24201230 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 69
Study 24201230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 69
Study 24201230 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed controls
Number of subjects: 69
Study 21613553 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt consumption
Number of subjects: 1080
Study 21613553 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt consumption >100 g/d
Number of subjects: 1080
Study 21613553 — intervention group
Group type: COMPARATOR
Intervention: Total dairy product, milk, and cheese consumption
Number of subjects: 1080
Study 19549290 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib 3 mg/kg per day
Number of subjects: 43
Study 19549290 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib 6 mg/kg per day
Number of subjects: 43
Study 19549290 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 43
Study 16684021 — intervention group
Group type: EXPERIMENTAL
Intervention: RF output titrated to avoid microbubble formation (Group I)
Number of subjects: 202
Study 16684021 — intervention group
Group type: COMPARATOR
Intervention: Standard power-limited RF output (Group II)
Number of subjects: 202
Study 16684021 — intervention group
Group type: COMPARATOR
Intervention: Group II (Control)
Number of subjects: 202
Study 16684021 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (Intervention)
Number of subjects: 202
Study 15031590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 270
Study 15031590 — intervention group
Group type: COMPARATOR
Intervention: Guided support groups
Number of subjects: 270
Study 15031590 — intervention group
Group type: COMPARATOR
Intervention: Natural course
Number of subjects: 270
Study 15031590 — intervention group
Group type: COMPARATOR
Intervention: Fatigued employees
Number of subjects: 270
Study 15031590 — intervention group
Group type: COMPARATOR
Intervention: Disease-free breast cancer patients
Number of subjects: 270
Study 15031590 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 270
Study 11231700 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium intervention
Number of subjects: 681
Study 11231700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 681
Study 9038130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5, 25, or 50 micromol/kg body weight) administered as an IV bolus
Number of subjects: 31
Study 9038130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA
Number of subjects: 31
Study 7912123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 7.5 g every 4 weeks for 1 year
Number of subjects: 35
Study 7912123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 40 g every 4 weeks for 1 year
Number of subjects: 35
Study 7912123 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV treatment (control group)
Number of subjects: 35
Study 2638869 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 2638869 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 0
Study 2638869 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 0
Study 2638869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 2638869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1167297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine alone
Number of subjects: 83
Study 1167297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and vinblastine
Number of subjects: 83
Study 1167297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and 6-mercaptopurine
Number of subjects: 83
Study 31148302 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 142
Study 31148302 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 142
Study 31148302 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptions in Foster Care Placement
Number of subjects: 142
Study 31724350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at experienced ten acupoints (Baihui, Zhongwan, Qihai, Tianshu, Neiguan, Zusanli, Gongsun, Danzhong)
Number of subjects: 62
Study 31724350 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint points with shallow puncture
Number of subjects: 62
Study 31724350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at experienced ten acupoints
Number of subjects: 62
Study 28554910 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily supportive SMS text messages for 6 months plus treatment as usual
Number of subjects: 0
Study 28554910 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 0
Study 26452544 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and recording skin temperatures with theory-based counselling
Number of subjects: 41
Study 26452544 — intervention group
Group type: COMPARATOR
Intervention: Standard foot care and recording foot inspections
Number of subjects: 41
Study 24205943 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 257
Study 24205943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 22924260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 0.1 J per point
Number of subjects: 66
Study 22924260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 1 J per point
Number of subjects: 66
Study 22924260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 4 J per point
Number of subjects: 66
Study 20651076 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum mesothelin levels in asbestos-exposed individuals
Number of subjects: 314
Study 20651076 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in mesothelin levels above the 95% confidence interval
Number of subjects: 314
Study 20651076 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum mesothelin as a biomarker
Number of subjects: 314
Study 18334495 — intervention group
Group type: COMPARATOR
Intervention: No planned distraction
Number of subjects: 40
Study 18334495 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call distraction
Number of subjects: 40
Study 18334495 — intervention group
Group type: EXPERIMENTAL
Intervention: TV show distraction
Number of subjects: 40
Study 18334495 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assignment distraction
Number of subjects: 40
Study 16162478 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]-R-PK11195 PET imaging in HIV+ patients with HAD
Number of subjects: 15
Study 16162478 — intervention group
Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in nondemented HIV+ patients
Number of subjects: 15
Study 16162478 — intervention group
Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in overall HIV+ patients (demented and nondemented)
Number of subjects: 15
Study 16162478 — intervention group
Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in patients with HAD
Number of subjects: 15
Study 12878619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg kg(‐1))
Number of subjects: 90
Study 12878619 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg kg(‐1))
Number of subjects: 90
Study 12878619 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml)
Number of subjects: 90
Study 10381027 — intervention group
Group type: EXPERIMENTAL
Intervention: One interviewer
Number of subjects: 487
Study 10381027 — intervention group
Group type: EXPERIMENTAL
Intervention: Two interviewers
Number of subjects: 487
Study 10381027 — intervention group
Group type: EXPERIMENTAL
Intervention: Two methods (self-completion and interviewer administration)
Number of subjects: 487
Study 10381027 — intervention group
Group type: COMPARATOR
Intervention: Change in method of administration
Number of subjects: 487
Study 9094875 — intervention group
Group type: EXPERIMENTAL
Intervention: Night meal (0100)
Number of subjects: 13
Study 9094875 — intervention group
Group type: EXPERIMENTAL
Intervention: Day meal (1300)
Number of subjects: 13
Study 9094875 — intervention group
Group type: COMPARATOR
Intervention: Control fasting reference line
Number of subjects: 13
Study 8345080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 60
Study 8345080 — intervention group
Group type: COMPARATOR
Intervention: Intra-uterine insemination (IUI)
Number of subjects: 60
Study 3578852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine with 1:300,000 epinephrine
Number of subjects: 100
Study 3578852 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 0.25% bupivacaine
Number of subjects: 100
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: VIT-2763 5/15/60/120/240 mg (SAD phase)
Number of subjects: 72
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: VIT-2763 60/120 mg once daily (MAD phase)
Number of subjects: 72
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: VIT-2763 60/120 mg twice daily (MAD phase)
Number of subjects: 72
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: VIT-2763 (all doses)
Number of subjects: 72
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: VIT-2763 120 mg once daily (MAD phase)
Number of subjects: 72
Study 31674058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27893567 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity home exercise program with 4 additional consults post-discharge (n = 26).
Number of subjects: 69
Study 27893567 — intervention group
Group type: COMPARATOR
Intervention: Usual ambulatory physical therapy (PT) (n = 43).
Number of subjects: 69
Study 26293170 — intervention group
Group type: EXPERIMENTAL
Intervention: adapalene gel with the active formulation
Number of subjects: 120
Study 26293170 — intervention group
Group type: COMPARATOR
Intervention: adapalene gel with the placebo
Number of subjects: 120
Study 26293170 — intervention group
Group type: COMPARATOR
Intervention: adapalene gel
Number of subjects: 120
Study 24119418 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (e‐magazine addressing health risks of sunbed use)
Number of subjects: 33
Study 24119418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 22627991 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (7 days treatment)
Number of subjects: 2029
Study 20522298 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding with skin-to-skin contact (group 1, n=35)
Number of subjects: 107
Study 20522298 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact without breastfeeding (group 2, n=36)
Number of subjects: 107
Study 20522298 — intervention group
Group type: COMPARATOR
Intervention: Control group (lying on the table, group 3, n=36)
Number of subjects: 107
Study 18482455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunionectomy, osteotomy, lateralization of the distal fragment, lateral release and medial capsulorrhaphy
Number of subjects: 115
Study 15912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light test at the slit lamp (Haag‐Streit, Switzerland)
Number of subjects: 28
Study 15912461 — intervention group
Group type: COMPARATOR
Intervention: WASCA (wave‐front analyser, Carl‐Zeiss‐Meditec)
Number of subjects: 28
Study 15912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 28
Study 12915819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir therapy (6 weeks of intravenous ganciclovir)
Number of subjects: 100
Study 12915819 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study 12915819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir therapy
Number of subjects: 100
Study 12915819 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 10574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-derived serine proteases (elastase, cathepsin G, proteinase 3)
Number of subjects: 39
Study 10574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastase
Number of subjects: 39
Study 10574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin G
Number of subjects: 39
Study 10574621 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-derived serine proteases
Number of subjects: 39
Study 8635647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic African-Americans
Number of subjects: 1086
Study 8635647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic Hispanics
Number of subjects: 1086
Study 8635647 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 1086
Study 8299622 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation interventions including physical training, risk factor modifications, and lifestyle changes.
Number of subjects: 0
Study 8299622 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed supervision in cardiac rehabilitation units or clinical conditions during early rehabilitation phase II.
Number of subjects: 0
Study 8299622 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programs initiated in acute phase I, convalescent phase II, and maintenance phase III after myocardial infarction.
Number of subjects: 0
Study 2935737 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 41
Study 2935737 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 41
Study 2935737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29893769 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg daily for 14 days
Number of subjects: 100
Study 29893769 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study 29893769 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in HR-positive/HER2-negative subgroup
Number of subjects: 100
Study 29893769 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 100
Study 27214258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant 100 mg twice a day
Number of subjects: 0
Study 27214258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant 150 mg twice a day
Number of subjects: 0
Study 27214258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant 200 mg twice a day
Number of subjects: 0
Study 27214258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25823174 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Precede‐Proceed Model
Number of subjects: 510
Study 22321451 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential outcomes procedure (DOP)
Number of subjects: 0
Study 22321451 — intervention group
Group type: COMPARATOR
Intervention: Non-differential outcomes condition
Number of subjects: 0
Study 20167446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled water pillow (15 degrees C) for 48 hours with restricted activity and medication (60 mg of prednisone for 7 days)
Number of subjects: 86
Study 20167446 — intervention group
Group type: COMPARATOR
Intervention: Control group received only medication (60 mg of prednisone for 7 days) without cooling and rest
Number of subjects: 86
Study 18702908 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet with supervised lifestyle intervention
Number of subjects: 52
Study 18702908 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle counseling
Number of subjects: 52
Study 15913526 — intervention group
Group type: EXPERIMENTAL
Intervention: Zadik procedure
Number of subjects: 83
Study 15913526 — intervention group
Group type: COMPARATOR
Intervention: Chemical ablation by sodium hydroxide
Number of subjects: 83
Study 12566475 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Group (1.6 g/(kg. d); CHO <40% of energy)
Number of subjects: 24
Study 12566475 — intervention group
Group type: COMPARATOR
Intervention: CHO Group (0.8 g/(kg. d); CHO >55%)
Number of subjects: 24
Study 9892860 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.75 mg s.c.)
Number of subjects: 8
Study 8539603 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive training exercises mounted as computer 'games' for 8 to 16 hours during a 20-day period.
Number of subjects: 0
Study 1912753 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (350 mg per week for 1 month, then random allocation to naltrexone for 6 months)
Number of subjects: 50
Study 1912753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (random allocation for 6 months)
Number of subjects: 50
Study 6756833 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-g/day vegetable protein diet
Number of subjects: 10
Study 6756833 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-g/day vegetable protein diet
Number of subjects: 10
Study 6756833 — intervention group
Group type: COMPARATOR
Intervention: 40-g/day meat protein diet plus neomycin-milk of magnesia
Number of subjects: 10
Study 30052800 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and healthy diet rich in N-3 PUFAs (RT-HD)
Number of subjects: 63
Study 30052800 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only (RT)
Number of subjects: 63
Study 30052800 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 63
Study 28969408 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT (Transobturator Tape)
Number of subjects: 206
Study 28969408 — intervention group
Group type: COMPARATOR
Intervention: TOT with cough stress test
Number of subjects: 206
Study 28969408 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT
Number of subjects: 206
Study 26111609 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg, subcutaneous, every 12 h from postoperative day 2 to 8)
Number of subjects: 30
Study 26111609 — intervention group
Group type: COMPARATOR
Intervention: IPC (intermittent pneumatic compression, continued until full ambulation)
Number of subjects: 30
Study 24859203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg)
Number of subjects: 315
Study 24859203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 21390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide slow release 1.5 mg, indapamide plus 2 mg perindopril, and indapamide plus 4 mg perindopril
Number of subjects: 0
Study 21390056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide plus 2 mg perindopril
Number of subjects: 0
Study 21390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide plus 4 mg perindopril
Number of subjects: 0
Study 21390056 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 19745590 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus paclitaxel (AT)
Number of subjects: 267
Study 19745590 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/doxorubicin/cyclophosphamide (FAC)
Number of subjects: 267
Study 17688720 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated intravenous crystalloid based on body weight (group 2)
Number of subjects: 33
Study 17688720 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluid (group 1)
Number of subjects: 33
Study 15449627 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic cloth paste (including silicone) with Dan‐shen root and azone
Number of subjects: 301
Study 15449627 — intervention group
Group type: COMPARATOR
Intervention: Elastic cloth paste (including silicone)
Number of subjects: 301
Study 11289042 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 (1.2 pmol x kg(−1) x min(−1))
Number of subjects: 16
Study 11289042 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1
Number of subjects: 16
Study 11289042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9647873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions to reduce hemoglobin S concentration to less than 30 percent of total hemoglobin concentration
Number of subjects: 130
Study 9647873 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130
Study 8059811 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg three times a day for 7 days)
Number of subjects: 80